Key facts
- It has raised $20K; the latest was Angel (individual) ($20K) in Aug 2025.
- Rhinal Therapeutics has filed 1 Form D with the SEC, most recently Aug 2025 ($20K sold to 1 investors).
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Rhinal Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Rhinal Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rhinal Therapeutics
Developer of nasal device technology intended for Intranasal Dry Powder GLP-1 treatment. The company offers engineered optimal particle size and slow, narrow plume for targeted delivery of 5mg to 40 mg of powder, optimized nozzle design for targeted dose, enabling users' ease of use for compliance and adherence.
- Sector
- Healthcare
- HQ
- Las Vegas, NV, United States
- Founded
- 2023
- Website
- rhinaltherapeutics.com/
- Ownership
- Privately Held (backing)
Rhinal Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rhinal Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rhinal Therapeutics in its N-PORT filings yet. We sweep new filings monthly.